Sunday, March 03, 2024 1:56:16 PM
This could move back to $1 or move to $4.
Chart looks interesting.
How will the big boys play here?
Good luck.
Recent OCEA News
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/22/2024 09:45:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter • GlobeNewswire Inc. • 10/22/2024 08:45:00 PM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses • GlobeNewswire Inc. • 10/01/2024 12:01:00 PM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms • GlobeNewswire Inc. • 08/27/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:30:33 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 08/23/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 09:26:10 PM
- Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 • GlobeNewswire Inc. • 06/05/2024 11:01:00 AM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 05/30/2024 11:44:00 AM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease • GlobeNewswire Inc. • 05/16/2024 12:01:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K • GlobeNewswire Inc. • 04/24/2024 08:51:06 PM
- Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL • GlobeNewswire Inc. • 03/28/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 10:22:43 PM
- Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting • GlobeNewswire Inc. • 02/29/2024 01:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 11:43:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:05:30 PM
FEATURED Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM
UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM